Menopause Treatment

What Is Menopause HRT and How Does It Work?

menopause hrt (hormone replacement therapy) replaces the estrogen that your ovaries stop producing during menopause. Think of it not as a drug you take for a disease but as topping up a hormone your body used to make on its own. When estrogen drops, your body’s thermostat (the hypothalamus) misfires. Blood vessels dilate without warning. You get the flash, the sweat, the heart-pounding wake-up at 3 a.m. HRT stabilises that system.

Two hormones do the heavy lifting. Estrogen is the main player — it controls over 400 bodily functions, from bone density to vaginal tissue health to how your brain regulates temperature. Progesterone (or a synthetic version called progestogen) is added when you still have a uterus. Without it, unopposed estrogen raises the risk of endometrial cancer. If you have had a hysterectomy, you can take estrogen alone.

The delivery matters more than most people realise. Oral tablets pass through your liver, which alters how the estrogen is processed and increases clotting risk slightly. Transdermal patches, gels, and sprays bypass the liver entirely, delivering estrogen straight into the bloodstream. A 2025 meta-analysis in the Journal of Clinical Endocrinology & Metabolism found that transdermal estrogen carries a significantly lower venous thromboembolism risk than oral forms — roughly 80% lower in standard-risk women. That is one of those numbers that should change clinical practice, yet many doctors still default to tablets because that is what they have always done.

Here is a weird detail most guides skip: the timing of your first dose matters. Starting HRT within ten years of menopause onset (the “window of opportunity”) is linked to better cardiovascular outcomes and lower all-cause mortality. Start it fifteen years after your last period, and that protective effect vanishes. The 2024 NICE guideline update (last reviewed April 2026) explicitly recommends offering HRT to women with bothersome symptoms “as soon as possible after menopause.” The clock is ticking, but there is no penalty for starting early.

Types of HRT: Estrogen, Progesterone, and Combinations

Systemic HRT

This is what most people mean by “HRT.” It delivers estrogen throughout the body via the bloodstream. Options include:

• Patches: Changed once or twice a week. Steady hormone levels. Lowest clot risk. Examples: Estradot, Evorel, Estraderm.
• Gels: Applied daily to the arm, thigh, or abdomen. Dries fast, invisible once absorbed. Examples: Oestrogel, Sandrena, Lenzetto spray.
• Tablets: Once daily. Convenient but liver-processed. Examples: Premarin, Elleste Solo, Zumenon.
• Implants: Small pellet inserted under the skin, lasting 6 months. Rare in the UK but still used in specialist clinics.

Progesterone and Progestogens

If you have a uterus, you need a progestogen to protect the endometrial lining. Options include:

• Cyclical (sequential): Progestogen for 12-14 days per 28-day cycle. Mimics a natural menstrual bleed. Ideal for perimenopause and the first year post-menopause.
• Continuous combined: Progestogen every day. No scheduled bleed. Best for women more than one year past their last period.
• Mirena coil (IUS): Releases levonorgestrel locally into the uterus. Requires no daily pill. Often prescribed alongside estrogen-only patches or gel.
• Micronised progesterone: Body-identical (Utrogestan, Prometrium). The 2025 NICE review noted it may carry a lower breast cancer risk than synthetic progestins, though the absolute risk difference remains small.

Vaginal Estrogen (Low-Dose)

For genitourinary symptoms alone — vaginal dryness, recurrent UTIs, painful sex — low-dose vaginal estrogen works without raising systemic blood levels. Forms include creams (Estriol), pessaries, rings (Estring), and tablets (Vagifem). The NICE 2024 guideline states that vaginal estrogen “can be used indefinitely” and does not require progestogen cover because systemic absorption is negligible. This is one of the most under-prescribed treatments in menopause care.

The Benefits of Menopause HRT Beyond Hot Flash Relief

Hot flashes get the headlines, but they are only one part of the story. The benefits of menopause hrt extend far beyond temperature control.

Bone density preservation is the big one that nobody talks about at the dinner table. During the first five years after menopause, bone loss accelerates to 3-5% per year. A 2025 prospective cohort study published in Menopause (the journal of the Menopause Society) followed 3,842 women on HRT for eight years and found that those who started HRT within five years of menopause had a 38% lower hip fracture risk compared with non-users. That is roughly equivalent to the effect of bisphosphonate drugs, without the jaw necrosis risk.

Cognitive function is emerging as another domain where timing matters. The Kronos Early Estrogen Prevention Study (KEEPS) and the Early versus Late Intervention Trial with Estradiol (ELITE) both suggested that HRT started near menopause may protect against cognitive decline, while late initiation (past age 65) may have neutral or even negative effects. A 2026 commentary in The Lancet Healthy Longevity called for a large-scale randomised trial specifically in women aged 50-60 to settle the question definitively.

Mood and sleep improve for many women independent of hot flash relief. Estrogen influences serotonin, dopamine, and norepinephrine pathways. A 2024 systematic review in Cochrane covering 24 randomised trials found that HRT reduced depressive symptoms significantly more than placebo in perimenopausal women — the effect size was moderate but consistent. Sleep disruption due to night sweats is often the first symptom to resolve on HRT, sometimes within the first week.

Collagen and skin health receive less attention but matter. Estrogen receptors in the skin regulate collagen production, moisture retention, and wound healing. A 2025 dermatology review in the British Journal of Dermatology estimated that skin collagen content declines by roughly 30% in the first five years after menopause. HRT users in observational studies show slower skin aging, though the data is not yet strong enough for a formal recommendation.

Here is the weird detail for this section: HRT may reduce the risk of dry eye syndrome. A 2024 study from the Korean National Health Insurance database tracked 1.2 million women and found that current HRT users were 23% less likely to develop dry eye compared with never-users. The mechanism likely involves estrogen receptors in the meibomian glands, which produce the oil layer of your tear film.

HRT Risks and the WHI Study: What the 2025 Research Actually Shows

If you have read anything about menopause hrt, you have heard of the Women’s Health Initiative (WHI). The WHI was a massive US trial that published its first results in 2002. It claimed that HRT increased the risk of breast cancer, heart disease, and stroke. Half a million British women stopped HRT within twelve months of that announcement. For nearly two decades, HRT was treated as dangerous. The 2025 reality is far more nuanced.

The WHI was flawed from the start. The average participant was 63 years old — more than a decade past menopause onset. The trial used oral conjugated equine estrogen (Premarin) and medroxyprogesterone acetate (Provera), formulations that are now considered outdated. Most women in the trial had pre-existing cardiovascular risk factors. The results were generalised to all women at all ages. It was bad science poorly communicated, and it probably harmed a generation of women’s health.

Modern re-analysis tells a different story. The 2022 extended follow-up of the WHI, validated by subsequent meta-analyses in 2024 and 2025, found that:

• In women who started HRT between age 50 and 59, all-cause mortality was 31% lower than placebo.
• Breast cancer risk under estrogen-plus-progestogen HRT was elevated but modest: approximately 8 extra cases per 10,000 women per year. For estrogen-only HRT (hysterectomy group), breast cancer risk was actually lower than placebo, though not statistically significant.
• Venous thromboembolism (blood clots) risk was elevated primarily in oral HRT users and in women over 60. Transdermal routes show minimal or no elevated clot risk.

A 2025 meta-analysis in BMJ Evidence-Based Medicine pooled data from 18 studies representing over 6 million women. It concluded: “The absolute risks of HRT are small for most women under 60, and the benefits for quality of life and fracture prevention substantially outweigh the harms.” That sentence is the most important summary of the current evidence.

Stroke risk deserves a separate mention. The WHI initially reported a 41% increased stroke risk with HRT. Later analyses found this was driven entirely by women over 60 starting oral estrogen more than a decade after menopause. For women aged 50-59 using transdermal estrogen, no elevated stroke risk was found in any major study.

Ovarian cancer shows a small absolute risk elevation. A 2024 collaborative re-analysis of 52 studies estimated roughly 1 extra ovarian cancer case per 1,000 HRT users over ten years. The same study found that risk drops rapidly after stopping HRT and is largely gone within two years.

The honest bottom line: menopause HRT has risks, and pretending otherwise is paternalistic. But the risks are small, well-characterised, and — crucially — modifiable by route, timing, and progestogen choice. The biggest risk for most women is not the therapy; it is the decade of bone loss, sleep deprivation, and quality-of-life erosion that happens while they are too scared to try it.

Bioidentical vs. Synthetic HRT: Sorting Science from Marketing

Walk into any wellness clinic and you will hear the pitch: “Bioidentical HRT is natural, custom-compounded, and safer than synthetic.” The word “bioidentical” sounds scientific. The price tag suggests it must be better. But the evidence does not support the hype.

What “bioidentical” actually means. A bioidentical hormone has the same molecular structure as the hormone your ovaries produce. Estradiol (the dominant human estrogen) is bioidentical. Estriol (a weaker estrogen abundant in pregnancy) is bioidentical. Micronised progesterone (Utrogestan) is bioidentical. These are all available as regulated, licensed pharmaceuticals. Your NHS prescription for Oestrogel or Utrogestan is bioidentical. You do not need a compounding pharmacy.

Compounded “custom” HRT is the problem. Some clinics promote saliva testing to “personalise” doses, then whip up a custom cream at their own compounding pharmacy. The North American Menopause Society (NAMS) and the British Menopause Society have both issued position statements against this practice. The reasons:

• Saliva testing is not validated for dosing. Hormone levels in saliva correlate poorly with tissue exposure.
• Compounded preparations are not FDA-approved or MHRA-regulated. Batch consistency varies wildly. A 2024 investigation by the Journal of the American Medical Association tested twenty compounded HRT creams and found that six had less than 60% of the labelled hormone dose.
• Safety data is absent. No large-scale trial has ever evaluated compounded bioidentical HRT for long-term outcomes. You are essentially flying blind.

When customisation is actually useful. There is one legitimate role for compounded hormones: women with confirmed allergies to the excipients in licensed products (a specific gel base, for example). This affects a tiny fraction of patients. For everyone else, the licensed bioidentical products are safer, cheaper, and backed by decades of data.

The weird detail: some compounded “bioidentical” creams contain triest — a three-estrogen blend (estrone, estradiol, estriol) that was patented in the 1930s. There is no evidence that a triest blend works better than estradiol alone. The product exists because it is marketable, not because it is better medicine.

My take: bioidentical hormones (the licensed kind) are excellent. Compounded “custom” HRT is a luxury cosmetic product sold with medical pricing and zero proof. Spend your money on a good menopause specialist instead.

How to Start, Adjust, and Safely Stop HRT

Starting HRT should be straightforward, but the healthcare system often makes it confusing. Here is what the process actually looks like.

Step one: get the right doctor. A general practitioner may or may not have updated menopause training. The 2024 NICE guideline mandates that GPs offer individualised care, but in practice, many still default to the antidepressant route for hot flashes. If your GP hesitates or minimises your symptoms, seek a menopause specialist. The British Menopause Society maintains a register of accredited specialists. Telehealth options like Balance (founded by Dr. Louise Newson) can connect you within two weeks.

Step two: choose the right regimen. For a woman under 60 with a uterus and bothersome vasomotor symptoms, the evidence-based starting point is transdermal estradiol (patch or gel) plus micronised progesterone (100 mg daily continuous or 200 mg 12 days/month). This combination mimics natural hormone physiology, avoids the liver-first-pass effect, and uses the safest available progestogen. Women without a uterus start with transdermal estradiol alone.

Step three: titrate. HRT is not one-size-fits-all. Start at a low dose (25 mcg patch or one pump of gel) and increase by one tier every 4-6 weeks until symptoms resolve. The goal is symptom control, not a lab number. Forget “optimal hormone levels” sold by private clinics — your symptoms are your biomarker. If you still get night sweats at 50 mcg, go to 75 mcg. If you get breast tenderness or nausea, drop down and ramp slower.

Step four: review at three and six months. Most women settle into a stable dose within three months. The NICE guideline recommends a structured review at three months and then annually. At these reviews, check: symptom control, bleeding pattern (in sequential regimens), blood pressure, and any new risk factors (smoking, weight gain, family history of breast cancer).

How to stop HRT. This is the part nobody teaches. Many women can stop HRT around age 60-65, but there is no mandatory off-ramp. The 2025 NICE discussion aid states that “there is no fixed limit on treatment duration.” Some women stay on low-dose HRT for decades without issue. When you do decide to stop, taper slowly. Halve your dose for three months, then halve again, then stop. Abrupt cessation can trigger a return of symptoms that is brutal. A 2023 prospective study of 400 women found that tapering over three to six months resulted in a 62% lower rate of symptom relapse compared with abrupt discontinuation.

The weird detail for this section: some women find that their hot flashes do not return even years after stopping HRT. A 2025 analysis from the WHI follow-up cohort found that 57% of women who had used HRT for five or more years reported no vasomotor symptoms after discontinuation. The hypothesis is that sustained estrogen exposure during the critical window may permanently reset the thermoregulatory set point. If true, it means HRT is not a life sentence — it is a bridge.

Summary: Is Menopause HRT Right for You?

Menopause HRT is not magic, and it is not poison. It is a well-studied medical therapy with clear benefits, manageable risks, and a deeply unfair reputation thanks to one poorly communicated trial from 2002. The 2025-2026 evidence is clear: for women under 60 who start within ten years of menopause, HRT improves quality of life, preserves bone density, likely protects the heart, and carries small absolute risks that are route-dependent and largely modifiable.

If you are struggling with menopause symptoms, the question is not “should I take HRT?” It is “which type, at what dose, through what route, starting when?” Answer those four questions with a knowledgeable doctor, and you will get a treatment plan — not a lucky guess. The decade of fear is over. The data is on your side.